Abstract 1555: Immune suppression of regulatory T cells and M2 macrophage in breast cancer patients

2011 ◽  
Author(s):  
Shigeru Imoto ◽  
Noriko Sakemura ◽  
Hiroki Ito ◽  
Kentaro Imi ◽  
Hirotsugu Isaka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Immune Suppression ◽  
M2 Macrophage ◽  
Breast Cancer Patients

scholarly journals Tumor specific regulatory T cells in the bone marrow of breast cancer patients selectively upregulate the emigration receptor S1P1

2017 ◽  
Vol 66 (5) ◽  
pp. 593-603 ◽  
Author(s):  
Anchana Rathinasamy ◽  
Christoph Domschke ◽  
Yingzi Ge ◽  
Hans-Henning Böhm ◽  
Steffen Dettling ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Breast Cancer Patients

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

2006 ◽  
Vol 24 (34) ◽  
pp. 5373-5380 ◽  
Author(s):  
Gaynor J. Bates ◽  
Stephen B. Fox ◽  
Cheng Han ◽  
Russell D. Leek ◽  
José F. Garcia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
At Risk ◽  
T Cells ◽  
High Risk ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Late Relapse ◽  
Breast Cancer Patients ◽  
Risk Of Relapse

Purpose To assess the clinical significance of tumor-infiltrating FOXP3-positive regulatory T cells (TR) in breast cancer patients with long-term follow-up. Patients and Methods FOXP3-positive TR were detected by immunohistochemistry with our new, extensively characterized FOXP3 monoclonal antibody, 236A/E7. Numbers of FOXP3-positive lymphocytes in tissue microarray cores from pure ductal carcinoma in situ (DCIS; n = 62), invasive breast cancer (n = 237) or from comparable areas of normal terminal duct lobular breast tissue (n = 10) were determined. A median cutoff of ≥ 15 defined patients with high numbers of TR. Results TR numbers were significantly higher in in situ and invasive breast carcinomas than in normal breast; invasive tumors have significantly higher numbers than DCIS (P = .001). High numbers of FOXP3-positive TR identified patients with DCIS at increased risk of relapse (P = .04) and patients with invasive tumors with both shorter relapse-free (P = .004) and overall survival (P = .007). High TR numbers were present in high-grade tumors (P ≤ .001), in patients with lymph node involvement (P = .01), and in estrogen receptor (ER) –negative tumors (P = .001). Importantly, high numbers of TR within ER-positive tumors identified high-risk patients (P = .005). Unlike conventional clinicopathologic factors, high numbers of FOXP3-positive TR can identify patients at risk of relapse after 5 years. Conclusion These findings indicate that quantification of FOXP3-positive TR in breast tumors is valuable for assessing disease prognosis and progression, and that TR are an important therapeutic target for breast cancer. FOXP3-positive TR represent a novel marker for identifying late-relapse patients who may benefit from aromatase therapy after standard tamoxifen treatment.

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

Vaccine ◽  
2010 ◽  
Vol 28 (47) ◽  
pp. 7476-7482 ◽  
Author(s):  
Jeremy D. Gates ◽  
Guy T. Clifton ◽  
Linda C. Benavides ◽  
Alan K. Sears ◽  
Mark G. Carmichael ◽  
...  
Keyword(s):  
Breast Cancer ◽  
T Cells ◽  
Regulatory T Cells ◽  
Cancer Patients ◽  
Mhc Class Ii ◽  
Class Ii ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document